Ovid Therapeutics Stock Analysis

Ovid Stock Analysis Notes

About 16.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.99. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Ovid Therapeutics recorded a loss per share of 0.46. The entity had not issued any dividends in recent years. Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company was incorporated in 2014 and is headquartered in New York, New York. Ovid Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people. To find out more about Ovid Therapeutics contact Zoology Dphil at 646 661 7661 or learn more at https://www.ovidrx.com.

Ovid Therapeutics Investment Alerts

Ovid Therapeutics Upcoming and Recent Events

Ovid Largest EPS Surprises

View All Earnings Estimates

Ovid Stock Institutional Investors

Note, although Ovid Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Ovid Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 75.27 M.

Ovid Profitablity

Management Efficiency

Ovid Therapeutics has return on total asset (ROA) of (0.3604) % which means that it has lost $0.3604 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3661) %, meaning that it created substantial loss on money invested by shareholders. Ovid Therapeutics' management efficiency ratios could be used to measure how well Ovid Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 23, 2024, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.47. At present, Ovid Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0, whereas Net Tangible Assets are forecasted to decline to about 81.7 M.

Technical Drivers

As of the 23rd of November, Ovid Therapeutics holds the Risk Adjusted Performance of (0.01), variance of 15.07, and Coefficient Of Variation of (3,860). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Ovid Therapeutics, as well as the relationship between them. Please check Ovid Therapeutics standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and kurtosis to decide if Ovid Therapeutics is priced some-what accurately, providing market reflects its current price of 1.05 per share. Given that Ovid Therapeutics is a hitting penny stock territory we advise to closely look at its jensen alpha.

Ovid Therapeutics Price Movement Analysis

Ovid Therapeutics Insider Trading Activities

Ovid Therapeutics Outstanding Bonds

Ovid Therapeutics Predictive Daily Indicators

Ovid Therapeutics Forecast Models

Ovid Therapeutics' time-series forecasting models are one of many Ovid Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ovid Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Ovid Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ovid shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Ovid Therapeutics. By using and applying Ovid Stock analysis, traders can create a robust methodology for identifying Ovid entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ovid analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ovid analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Ovid Therapeutics stock analysis indicators help investors evaluate how Ovid Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ovid Therapeutics shares will generate the highest return on investment. By understating and applying Ovid Therapeutics stock analysis, traders can identify Ovid Therapeutics position entry and exit signals to maximize returns.

When running Ovid Therapeutics' price analysis, check to measure Ovid Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ovid Therapeutics is operating at the current time. Most of Ovid Therapeutics' value examination focuses on studying past and present price action to predict the probability of Ovid Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ovid Therapeutics' price. Additionally, you may evaluate how the addition of Ovid Therapeutics to your portfolios can decrease your overall portfolio volatility.